Increased glucose metabolism and ATP level in brain tissue of Huntington's disease transgenic mice

FEBS Journal

Volumn 275, Issue 19, 2008, Pages 4740-4755

  Oláh, Judit ^a   Klivényi, Péter ^b   Gardián, Gabriella ^b   Vécsei, László ^b   Orosz, Ferenc ^a   Kovacs, Gabor G ^c   Westerhoff, Hans V ^d,e   Ovádi, Judit ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d VU UNIVERSITY AMSTERDAM   (Netherlands)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Biosimulation; Channelling; Energy metabolism; Glycolysis activation; Huntington's disease

Indexed keywords

3 NITROPROPIONIC ACID; ADENOSINE TRIPHOSPHATE; FRUCTOSE BISPHOSPHATE ALDOLASE; GLUCOSE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GLYCOLYTIC ENZYME; HUNTINGTIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE);

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; BRAIN TISSUE; CHEMICAL ANALYSIS; CONTROLLED STUDY; ENERGY METABOLISM; ENZYME ACTIVITY; FEMALE; GLUCOSE METABOLISM; GLYCOLYSIS; HUNTINGTON CHOREA; IMMUNOHISTOCHEMISTRY; MALE; MATHEMATICAL MODEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION;

ADENOSINE TRIPHOSPHATE; ANIMALS; BRAIN; CREATINE; FEMALE; GLUCOSE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE (PHOSPHORYLATING); GLYCOLYSIS; HUNTINGTON DISEASE; MALE; MICE; MICE, TRANSGENIC; MITOCHONDRIA; NERVE TISSUE PROTEINS; NITRO COMPOUNDS; NUCLEAR PROTEINS; PROPIONIC ACIDS;

MUS; MUS MUSCULUS;

EID: 51749107237     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2008.06612.x     Document Type: Article

References (52)

1. Purdon SE, Mohr E, Ilivitsky V Jones BD (1994) Huntington's disease: pathogenesis, diagnosis and treatment. J Psychiatry Neurosci 19, 359 367.
2. Walker FO (2007) Huntington's disease. Lancet 369, 218 228.
3. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP Aronin N (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277, 1990 1993.
4. The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971 983.
5. Perez-De La Cruz V Santamaria A (2006) Integrative hypothesis for Huntington's disease: a brief review on experimental evidence. Physiol Res 56, 513 526.
6. Landles C Bates GP (2004) Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in molecular medicine review series. EMBO Rep 5, 958 963.
7. Beal MF (2000) Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci 23, 298 304.
8. Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muqit MM, Bird ED Beal MF (1997) Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann Neurol 41, 646 653.
9. Gu M, Gash MT, Mann VM, Javoy-Agid F, Cooper JM Schapira AH (1996) Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol 39, 385 389.
10. Jenkins BG, Koroshetz WJ, Beal MF Rosen BR (1993) Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. Neurology 43, 2689 2695.
11. Sanchez-Pernaute R, Garcia-Segura JM, del Barrio Alba A, Viano J de Yebenes JG (1999) Clinical correlation of striatal 1H MRS changes in Huntington's disease. Neurology 53, 806 812.
12. Hoang TQ, Bluml S, Dubowitz DJ, Moats R, Kopyov O, Jacques D Ross BD (1998) Quantitative proton-decoupled 31P MRS and 1H MRS in the evaluation of Huntington's and Parkinson's diseases. Neurology 50, 1033 1040.
13. Ma Y Eidelberg D (2007) Functional imaging of cerebral blood flow and glucose metabolism in Parkinson's disease and Huntington's disease. Mol Imaging Biol 9, 223 233.
14. Burke JR, Enghild JJ, Martin ME, Jou Y-S, Myers RM, Roses AD, Vance JM Strittmatter WJ (1996) Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH. Nat Med 2, 347 350.
15. Kish SJ, Lopes-Cendes I, Guttman M, Furukawa Y, Pandolfo M, Rouleau GA, Ross BM, Nance M, Schut L, Ang L et al. (1998) Brain glyceraldehyde-3-phosphate dehydrogenase activity in human trinucleotide repeat disorders. Arch Neurol 55, 1299 1304.
16. Cooper AJ, Sheu KF, Burke JR, Strittmatter WJ Blass JP (1998) Glyceraldehyde-3-phosphate dehydrogenase abnormality in metabolically stressed Huntington disease fibroblasts. Dev Neurosci 20, 462 468.
17. Mazzola JL Sirover MA (2001) Reduction of glyceraldehyde-3-phosphate dehydrogenase activity in Alzheimer's disease and in Huntington's disease fibroblasts. J Neurochem 76, 442 449.
18. Senatorov VV, Charles V, Reddy PH, Tagle DA Chuang DM (2003) Overexpression and nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase in a transgenic mouse model of Huntington's disease. Mol Cell Neurosci 22, 285 297.
19. Bae BI, Hara MR, Cascio MB, Wellington CL, Hayden MR, Ross CA, Ha HC, Li XJ, Snyder SH Sawa A (2006) Mutant huntingtin: nuclear translocation and cytotoxicity mediated by GAPDH. Proc Natl Acad Sci USA 103, 3405 3409.
20. Menalled LB Chesselet MF (2002) Mouse models of Huntington's disease. Trends Pharmacol Sci 23, 32 39.
21. Klivenyi P, Starkov AA, Calingasan NY, Gardian G, Browne SE, Yang L, Bubber P, Gibson GE, Patel MS Beal MF (2004) Mice deficient in dihydrolipoamide dehydrogenase show increased vulnerability to MPTP, malonate and 3-nitropropionic acid neurotoxicity. J Neurochem 88, 1352 1360.
22. Brouillet E, Conde F, Beal MF Hantraye P (1999) Replicating Huntington's disease phenotype in experimental animals. Prog Neurobiol 59, 427 468.
23. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotypes in transgenic mice. Cell 87, 493 506.
24. Schilling G, Becher MW, Sharp AH, Jinnah HA, Duan K, Kotzuk JA, Slunt HH, Ratovitski T, Cooper JK, Jenkins NA et al. (1999) Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet 8, 397 407.
25. Klivenyi P, Bende Z, Hartai Z, Penke Z, Nemeth H, Toldi J Vecsei L (2006) Behaviour changes in a transgenic model of Huntington's disease. Behav Brain Res 169, 137 141.
26. Hedreen JC Folstein SE (1995) Early loss of neostriatal striosome neurons in Huntington's disease. J Neuropathol Exp Neurol 54, 105 120.
27. Teusink B, Passarge J, Reijenga CA, Esgalhado E, van der Weijden CC, Schepper M, Walsh MC, Bakker BM, van Dam K, Westerhoff HV et al. (2000) Can yeast glycolysis be understood in terms of in vitro kinetics of the constituent enzymes? Testing biochemistry. Eur J Biochem 267, 5313 5329.
28. Snoep JL, Bruggeman F, Olivier BG Westerhoff HV (2006) Towards building the silicon cell: a modular approach. Biosystems 83, 207 216.
29. Westerhoff HV, Kolodkin A, Conradie R, Wilkinson SJ, Bruggeman FJ, Krab K, van Schuppen JH, Hardin H, Bakker BM, Moné MJ et al. (2008) Systems biology towards life in silico: mathematics of the control of living cells. J Math Biol [Epub ahead of print].
30. Wu J, Takeo T, Wakui M, Ellsworth K Fisher RS (2003) Intracellular energy failure does not underlie hyperthermic spreading depressions in immature rat hippocampal slice. Brain Res 987, 240 243.
31. Aubert A Costalat R (2002) A model of the coupling between brain electrical activity, metabolism, and hemodynamics: application to the interpretation of functional neuroimaging. Neuroimage 17, 1162 1181.
32. Gusella JF MacDonald ME (2000) Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease. Nat Rev Neurosci 1, 109 115.
33. Arrasate M, Mitra S, Schweitzer ES, Segal MR Finkbeiner S (2004) Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431, 805 810.
34. Marcinek DJ (2004) Mitochondrial dysfunction measured in vivo. Acta Physiol Scand 182, 343 352.
35. Seong IS, Ivanova E, Lee JM, Choo YS, Fossale E, Anderson M, Gusella JF, Laramie JM, Myers RH, Lesort M et al. (2005) HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum Mol Genet 14, 2871 2880.
36. Kasparová S, Sumbalová Z, Bystrický P, Kucharská J, Liptaj T, Mlynárik V Gvozdjáková A (2006) Effect of coenzyme Q10 and vitamin E on brain energy metabolism in the animal model of Huntington's disease. Neurochem Int 48, 93 99.
37. Andreassen OA, Dedeoglu A, Ferrante RJ, Jenkins BG, Ferrante KL, Thomas M, Friedlich A, Browne SE, Schilling G, Borchelt DR et al. (2001) Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol Dis 8, 479 491.
38. Matthews RT, Yang L, Jenkins BG, Ferrante RJ, Rosen BR, Kaddurah-Daouk R Beal MF (1998) Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. J Neurosci 18, 156 163.
39. van der Burg JM, Bacos K, Wood NI, Lindqvist A, Wierup N, Woodman B, Wamsteeker JI, Smith R, Deierborg T, Kuhar MJ et al. (2008) Increased metabolism in the R6/2 mouse model of Huntington's disease. Neurobiol Dis 29, 41 51.
40. Ovádi J (1995) Cell Architecture and Metabolic Channeling. Springer-Verlag, New York, NY.
41. Jenkins BG, Andreassen OA, Dedeoglu A, Leavitt B, Hayden M, Borchelt D, Ross CA, Ferrante RJ Beal MF (2005) Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's disease. J Neurochem 95, 553 562.
42. Jenkins BG, Klivenyi P, Kustermann E, Andreassen OA, Ferrante RJ, Rosen BR Beal MF (2000) Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice. J Neurochem 74, 2108 2119.
43. Guidetti P, Charles V, Chen EY, Reddy PH, Kordower JH, Whetsell WOJ, Schwarcz R Tagle DA (2001) Early degenerative changes in transgenic mice expressing mutant huntingtin involve dendritic abnormalities but no impairment of mitochondrial energy production. Exp Neurol 169, 340 350.
44. Saulle E, Gubellini P, Picconi B, Centonze D, Tropepi D, Pisani A, Morari M, Marti M, Rossi L, Papa M et al. (2004) Neuronal vulnerability following inhibition of mitochondrial complex II: a possible ionic mechanism for Huntington's disease. Mol Cell Neurosci 25, 9 20.
45. Ovádi J Orosz F (2007) Energy metabolism in conformational diseases. In Biosimulation in Drug Development (Bertau M, Mosekilde E Westerhoff H, eds pp. 233 257. Wiley, Weinheim.
46. Chih CP, Lipton P Roberts ELJ (2001) Do active cerebral neurons really use lactate rather than glucose? Trends Neurosci 24, 573 578.
47. Pellerin L Magistretti PJ (1994) Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. Proc Natl Acad Sci USA 91, 10625 10629.
48. Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ Piccini P (2007) Imaging microglial activation in Huntington's disease. Brain Res Bull 72, 148 151.
49. Almeida A, Almeida J, Bolanos JP Moncada S (2001) Different responses of astrocytes and neurons to nitric oxide: the role of glycolytically generated ATP in astrocyte protection. Proc Natl Acad Sci USA 98, 15294 15299.
50. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72, 248 254.
51. Beutler E, Blume KG, Kaplan JC, Löhr GW, Ramot B Valentine WN (1977) International Committee for Standardization in Haematology: recommended methods for red-cell enzyme analysis. Br J Haematol 35, 331 340.
52. Barrientos A, Kenyon L Moraes CT (1998) Human xenomitochondrial cybrids. Cellular models of mitochondrial complex I deficiency. J Biol Chem 273, 14210 14217.